EYPT
TechnologyEyePoint Pharmaceuticals Inc
Live · NASDAQ · May 9, Close
What's Moving EYPT Today?
No stock-specific AI insight has been generated for EYPT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
EYPT News
20 articles- EyePoint (EYPT) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Eyepoint Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- EyePoint (EYPT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 6, 2026
- Is It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price SurgeYahoo Finance·May 6, 2026
- EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsYahoo Finance·May 6, 2026
- How The EyePoint (EYPT) Story Is Shifting With DURAVYU And Phase 3 DME TrialsYahoo Finance·May 5, 2026
- EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 29, 2026
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Apr 16, 2026
- Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?Yahoo Finance·Apr 2, 2026
- EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology ConferenceMarketbeat·Mar 25, 2026
- How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In FocusYahoo Finance·Mar 21, 2026
- This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?Motley Fool·Mar 16, 2026
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover DealMotley Fool·Mar 16, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMotley Fool·Mar 16, 2026
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterMotley Fool·Mar 16, 2026
- This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share InvestmentMotley Fool·Mar 15, 2026
- Is It Too Late To Consider EyePoint (EYPT) After Its 173% One Year Surge?Yahoo Finance·Mar 5, 2026
- EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ...Yahoo Finance·Mar 4, 2026
- EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 4, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About EyePoint Pharmaceuticals Inc
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.